KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Liabilities: 2020-2025

Historic Total Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $392.0 million.

  • AbCellera Biologics' Total Liabilities rose 24.54% to $392.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.0 million, marking a year-over-year increase of 24.54%. This contributed to the annual value of $304.5 million for FY2024, which is 9.32% down from last year.
  • As of Q3 2025, AbCellera Biologics' Total Liabilities stood at $392.0 million, which was down 0.77% from $395.0 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Total Liabilities ranged from a high of $395.0 million in Q2 2025 and a low of $171.4 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $329.4 million (2023), whereas its average is $332.6 million.
  • As far as peak fluctuations go, AbCellera Biologics' Total Liabilities skyrocketed by 124.49% in 2022, and later declined by 24.78% in 2023.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Total Liabilities stood at $292.8 million in 2021, then rose by 5.05% to $307.6 million in 2022, then rose by 9.15% to $335.8 million in 2023, then decreased by 9.32% to $304.5 million in 2024, then rose by 24.54% to $392.0 million in 2025.
  • Its last three reported values are $392.0 million in Q3 2025, $395.0 million for Q2 2025, and $321.2 million during Q1 2025.